The Patent Finder

Midwestern University

15 patents currently held · Updated Nov 15, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

4
Ending by 2030
Aug 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Inhibitors of β-hydroxylase for treatment of cancer (US 10,351,555) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 2 fees due Aug 13 to 18, 2027 · next Aug 13

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,493,524Methods for Treatment of Stroke or Cerebrovascular Accidents Using an Etb Receptor Agonist
In force
 · Medium confidence
In forceMedium confidence
US 10,112,981Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist
In force
 · Medium confidence
In forceMedium confidence
US 8,623,823Methods for Treatment of Stroke or Cerebrovascular Accidents Using an Etb Receptor Agonist
In force
 · High confidence
In forceHigh confidence
US 10,828,368Therapeutic treatments using centhaquin
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,106,532Inhibitors of beta-hydroxylase for treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,351,555Inhibitors of β-hydroxylase for treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,710,995Inhibitors of β-hydroxylase for treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,787,445Inhibitors of beta-hydroxylase for treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,561,704Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,688,195Polymyxin B-Coated Nanoparticles
In force
 · High confidence
In forceHigh confidence
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 1 patent in force now held by others · 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited